
    
      The purpose of this study is a preliminary assessment of the Octohydroaminoacridine Succinate
      tablets in the treatment of mild to moderate Alzheimer's disease and explore the efficacy and
      safety of the best dose. The 288 patients were randomly assigned to four groups: high dose
      (4mg / time), moderate dose (2mg / time), low dose (1mg / time) and the placebo group,
      including four weeks of the trial screening period following 16 weeks double-blind treatment.
    
  